Skip to main content

09-14-2017 | PCSK9 inhibitors | EASD 2017 | News

News in brief

Alirocumab dyslipidemia benefits extended to type 1 patients

medwireNews: The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

Helen Colhoun (University of Edinburgh, UK) reported at the EASD annual meeting in Lisbon, Portugal, that the 49 patients taking alirocumab achieved an average 1.6 mmol/L (61.7 mg/dL) absolute reduction in low-density lipoprotein (LDL) cholesterol during 24 weeks of treatment. This amounted to a 47.8% reduction when compared with the 25 patients who were taking placebo.

The patients were aged an average of 56.1 years and were already taking the maximum tolerated statin dose or were intolerant to statins. The LDL cholesterol reduction occurred during the first 8 weeks of taking alirocumab, and it remained consistent to the end of follow-up. Of the alirocumab-treated patients, 70.2% met their LDL cholesterol target and 79.0% met their non-high-density lipoprotein cholesterol goal. For most, this was achieved on the lower 75 mg alirocumab dose, with 36.7% requiring uptitration to the higher 150 mg dose.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

Related topics